CNCE News 8.90 04/26/2014 00:31:37 Concert Pharmaceuticals Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Concert Pharmaceuticals Inc. (CNCE) 8.90 $CNCE

Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease
Business Wire - Fri Apr 25, 1:00PM CDT
--- CTP-499 reduced biomarkers of fibrosis -

Concert Pharmaceuticals, Inc. [CNCE] to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Fri Apr 11, 9:00AM CDT
What:

Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014

Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.

Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.

Concert Pharmaceuticals Reports Year End 2013 Financial Results
Business Wire - Mon Mar 31, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting
Business Wire - Wed Mar 19, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that 48 week Phase 2 clinical results of CTP-499 in patients with diabetic kidney disease will be presented at the National Kidney Foundation 2014 Spring Clinical Meeting. The meeting will take place on April 22-26, 2014 at the MGM Grand in Las Vegas, NV. The podium presentation will be made by the lead author, Dr. Bhupinder Singh, a clinical investigator for the study at Southwest Clinical Research Institute, to present the clinical results during the Late Breaking Session on Friday, April 25, 2014, 9:30 am - 11:00 am PDT. A corresponding poster presentation will also be presented at the meeting and will include data describing the effect of CTP-499 treatment on several biomarkers of fibrosis. A copy of the corresponding abstract is available on the National Kidney Foundation's website at: http://www.kidney.org/news/meetings/clinical/.../index.cfm.

Concert Pharmaceuticals elects Dr Wendell Wierenga to board
M2 - Mon Mar 17, 5:05AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) revealed on Friday the addition of Dr Wendell Wierenga, PhD to its board of directors.

Company Profile for Concert Pharmaceuticals, Inc.
Business Wire - Fri Mar 14, 9:40AM CDT
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer.

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors
Business Wire - Fri Mar 14, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today the appointment of Wendell Wierenga, Ph.D. to its board of directors. Dr. Wierenga is a seasoned executive with broad experience across all aspects of research, drug discovery and drug development including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. Over the course of his career, he has been involved in over 70 INDs, 15 NDAs and 16 marketed products, including Lipitor(R), Neurontin(R), and Uceris(R).

Concert Pharmaceuticals Announces Exercise of Over-Allotment Option
Business Wire - Mon Mar 03, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the underwriters for its initial public offering of common stock have exercised their over-allotment option and purchased an additional 649,690 shares. The additional shares were sold at the public offering price of $14.00 per share, before underwriting discounts. The closing occurred on March 3, 2014, bringing the total number of shares sold by Concert in the initial public offering to 6,649,690 shares, which represents a total capital raise of approximately $93 million before underwriting discounts.

Concert Pharmaceuticals to Present at the 26th Annual ROTH Conference on March 10, 2014
Business Wire - Mon Mar 03, 6:00AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will present a corporate overview at the 26th Annual ROTH Conference on Monday, March 10, 2014 at 9:00 a.m. PDT at the Ritz-Carlton Laguna Niguel, CA.

Concert Pharmaceuticals concludes IPO of 6m common shares
M2 - Thu Feb 20, 5:20AM CST
US-based biopharmaceutical company Concert Pharmaceuticals Inc (NasdaqGM:CNCE) revealed on Wednesday the completion of its initial public offering of 6m shares of its common stock.

Concert Pharmaceuticals Announces Closing of Initial Public Offering
Business Wire - Wed Feb 19, 10:30AM CST
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the closing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts.

Concert Pharmaceuticals Announces Pricing of Initial Public Offering
Business Wire - Thu Feb 13, 7:00AM CST
Concert Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts. In addition, Concert has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of common stock at the same price to cover over-allotments. The shares are scheduled to begin trading on the NASDAQ Global Market on February 13, 2014 under the ticker symbol "CNCE."

Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Business Wire - Thu Jan 23, 6:00AM CST
Concert Pharmaceuticals, Inc. today announced the appointment of Ryan Daws as Chief Financial Officer. Mr. Daws brings to Concert more than 15 years of capital markets and financial advisory experience in the biotechnology and healthcare industry.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Daymond John's Four-Center Bet on Longevity Game

Updated Category News Views 42

A Shark's Dive into Longevity Here you go—Daymond John, the face of FUBU and a household name from Shark Tank, is not just talking about living longer; he's putting his wallet where his words are. John is jumping into the longevity game with both feet, joining Ultimate Longevity Center's (ULC) latest venture. We're talking about four new centers across California,...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 174

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 15

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 203

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 22

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 15

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 282

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 113

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading

Top 5 Most Recently Viewed Articles

BIEL Crystal's Innovative Smartphone Glass Cover Revolutionizes Durability

Updated Category News Views 299

BIEL Crystal's Innovative Smartphone Glass Cover BIEL Crystal, a notable supplier for Apple and a leader in smart device components, has recently introduced its cutting-edge product, the "Witch Cloak." This ultra-hard coating smartphone glass cover represents a significant advancement in the technology used to protect smartphones from daily wear and tear, notably featured...

Continue Reading
Covenant Clearinghouse Triumphs in Legal Battle with Chicago Title

Updated Category News Views 780

Covenant Clearinghouse Triumphs in Legal Battle Covenant Clearinghouse recently achieved a significant legal victory against the Chicago Title Company, concluding a complex litigation case. The case, documented as Chicago Title Ins. Co. v. Covenant Clearinghouse, LLC, revolved around crucial property rights under the Illinois Transfer Fee Covenant Act. Legal Proceedings...

Continue Reading
TTEC CEO's Buyout Proposal: What It Means for Stakeholders

Updated Category News Views 137

TTEC's CEO Buyout Proposal: Evaluating the Future TTEC Holdings, Inc. (NASDAQ: TTEC), known for its AI-driven customer experience solutions, is currently assessing a buyout proposal presented by its CEO, Kenneth Tuchman. This significant move has prompted the company to engage the services of Rothschild & Co as its financial advisor, alongside legal support from Skadden,...

Continue Reading
Primech AI Unveils HYTRON LITE Bathroom Cleaning Solution

Updated Category News Views 167

Primech AI Launches Innovative HYTRON LITE at Industry Event Primech AI Pte. Ltd. (Nasdaq: PMEC) is making waves in the robotics industry with its latest innovative creation, the HYTRON LITE bathroom cleaning robot, introduced during a significant event focused on facilities management. This gathering, that united key players, took place at Temasek Polytechnic and was...

Continue Reading
The Growth Journey of Travelers Companies: A Five-Year Analysis

Updated Category News Views 255

Understanding Travelers Companies' Market Performance When evaluating the potential return on investment in stocks, it's essential to look at the historical performance of companies like Travelers Companies (NYSE: TRV). This prominent insurance provider has shown remarkable consistency and growth over the years, recently achieving a market capitalization of $63.96...

Continue Reading